Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases

• Main Authors: Regula, J.T, Lundh von Leithner, P, Foxton, R, Barathi, V.A, Cheung, C.M.G, Bo Tun, S.B, Wey, Y.S, Iwata, D, Dostalek, M, Moelleken, J, Stubenrauch, K.G, Nogoceke, E, Widmer, G, Strassburger, P, Koss, M.J, Klein, C, Shima, D.T, Hartmann, G
• Other Authors: OPHTHALMOLOGY
• Format: Article
• Published: 2020
• Subjects: angiopoietin 2; CD16 antigen; monoclonal antibody; rg 7716; unclassified drug; vasculotropin A; vasculotropin A antibody; vasculotropin antibody; immunologic factor; angiogenesis; animal experiment; animal model; Article; binding site; cross reaction; drug clearance; drug efficacy; drug potency; drug protein binding; eye disease; human; monotherapy; mouse; nonhuman; priority journal; protein depletion; protein targeting; retina edema; retina vasculitis; subretinal neovascularization; upregulation; vitreous body; animal; antagonists and inhibitors; disease model; Eye Diseases; isolation and purification; Macaca fascicularis; Neovascularization, Pathologic; pathology; preclinical study; treatment outcome; Angiopoietin-2; Animals; Antibodies, Monoclonal; Disease Models, Animal; Drug Evaluation, Preclinical; Immunologic Factors; Treatment Outcome; Vascular Endothelial Growth Factor A
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/179906
• Institution: National University of Singapore

10.15252/emmm.201505889